Unique Solid Dispersions by Microwave Fusion Technique with Etoricoxib and Thiocolchicoside: In vivo Evaluation and Comparison with Marketed Formulation

Abstract

Aim: The primary objective of the study is to evaluate solid dispersion (SDs) made into tablets containing Etoricoxib (ECB) and Thiocolchicoside (TCS) for different in vivo parameters and in vitro drug release as an extension of the work described by Annepogu et al., in 2018. Methods: The in vitro study was constructed on various evaluation parameters of SDs of ECB and TCS. From earlier study results, we have selected formula-5 SDs of ECB and TCS for in-vivo study and comparison with marketed ones. Results: Plasma drug availability was performed on 6 healthy rabbits of both sexes (weighing 2.0-2.5 kg). They were aimlessly alienated into 2 groups of alike size by parallel design. Later, the study was HPLC analysis of the drug in the plasma, which involved preparation of the spiked plasma sample, and an analytical technique was established (simple and cost-effective method for ECB and TCS simultaneous estimation). The plasma samples were assessed for pharmacokinetic parameters. Finally, the F-5 formulation was assessed for in vitro drug release by comparison with the marketed preparation (Recox tablets-Hochest Biotech India). Conclusion: The study summarizes that TCS and ECB reached systemic circulation better than the pure drugs, and the kinetic values were appreciable. The drug discharge from the SDs was identical to the marketed one.